Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL354779 | 0.97 | MGLL (0.39) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL29017 | 0.77 | MGLL (0.45) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL43978 | 0.77 | MGLL (0.45) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL31185062 | 0.76 | MGLL (0.39) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL24574686 | 0.75 | ALDH1A1 (0.36) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL22503763 | 0.74 | MGLL (0.38) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL331187 | 0.72 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL22289873 | 0.72 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL13968985 | 0.72 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL24024169 | 0.72 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-03-10 | — | — | US | claimed |
| CN-111514286-B | Zika virus E protein conjugate vaccine and preparation method thereof | 中国科学院过程工程研究所 | 2022-03-08 | — | — | CN | claimed |
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2021-07-29 | — | — | US | claimed |
| EP-3703666-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | Universidade de Santiago de Compostela (ES) | 2020-09-09 | — | — | EP | claimed |
| US-6274325-B1 | USING A FAB'-BIOTIN MATERIAL AND AGGLUTINATABLE PARTICLES WHICH CARRY STREPTAVIDIN OR AVIDIN | BOEHRINGER MANNHEIM GMBH (DE) | 2001-08-14 | — | — | US | claimed |
| US-20260102500-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING | SMARTDYELIVERY GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| US-12599663-B2 | Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation | VALITOR, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720089-A1 | COMPOSITIONS AND METHODS FOR IMAGING AND TREATING ENDOMETRIOSIS | Endomet Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250354056-A1 | POLYMER DOTS | BIO RAD LABORATORIES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | SMARTDYELIVERY GMBH (DE) | 2025-11-18 | — | — | US | disclosed |
| EP-4638489-A1 | PROTEIN-BASED CONJUGATION CARRIERS | Ablynx N.V. (BE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4601648-A2 | ACRIDINIUM COMPOUNDS WITH FUSED HETEROCYCLES | Siemens Healthcare Diagnostics Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-1998026644-A9 | CONFIRMATORY ASSAYS FOR SMALL MOLECULE DRUGS | MICROGENICS CORP (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998054133-A1 | CONJUGATES AND SPECIFIC IMMUNOASSAYS FOR THE METHADONE METABOLITE 2-ETHYLIDINE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE | MICROGENICS CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998053316-A1 | ASSAYS EMPLOYING ELECTROCHEMILUMINESCENT LABELS AND ELECTROCHEMILUMINESCENCE QUENCHERS | BOEHRINGER MANNHEIM CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998026644-A2 | CONFIRMATORY ASSAYS FOR SMALL MOLECULE DRUGS | MICROGENICS CORPORATION (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0742903-A1 | PIPERIDINE ANALOGS AND CONJUGATES OF PROCAINAMIDE AND NAPA | BOEHRINGER MANNHEIM CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5525474-A | IMMUNOASSAY; LINKING THE HAPTENIC DRUG VIA ITS MALEIMIDE MOIETY AND A SULFHYDRYL BRIDGE TO AN IMMUNOGENIC CARRIER TO STIMULATE ANTIBODIES | BOEHRINGER MANNHEIM CORPORATION (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1995020763-A1 | PIPERIDINE ANALOGS AND CONJUGATES OF PROCAINAMIDE AND NAPA | BOEHRINGER MANNHEIM CORPORATION (US) | 1995-08-03 | — | — | WO | disclosed |
| EP-0303406-A2 | An immunoaffinity substrate | Hewlett-Packard Company (US) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599663-B2 | Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation | CD44, ICAM1, CD40 | MGLL 4698/4885GSK3A 3927/4885GSK3B 3299/4885 |
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | LNPEP, CLIC1, CLSPN | MGLL 2631/4885GSK3A 4583/4885GSK3B 4690/4885 |
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | LNPEP, CLIC1, CLSPN | MGLL 2631/4885GSK3A 4583/4885GSK3B 4690/4885 |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | PRKCH, PRKCZ, PIKFYVE | MGLL 962/4885GSK3A 283/4885GSK3B 277/4885 |
| US-20260102500-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING | PRKCE, PRKCI, PRKCZ | MGLL 1193/4885GSK3A 125/4885GSK3B 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.